Published in NeuroRx on January 01, 2006
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Upward spirals of positive emotions counter downward spirals of negativity: insights from the broaden-and-build theory and affective neuroscience on the treatment of emotion dysfunctions and deficits in psychopathology. Clin Psychol Rev (2010) 2.22
Frontal-subcortical circuitry and behavior. Dialogues Clin Neurosci (2007) 2.14
Antidepressants recruit new neurons to improve stress response regulation. Mol Psychiatry (2011) 2.11
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
Bipolar disorder: from genes to behavior pathways. J Clin Invest (2009) 1.24
Pharmacological treatments that facilitate extinction of fear: relevance to psychotherapy. NeuroRx (2006) 1.20
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17
Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One (2008) 1.17
G protein-coupled receptors in major psychiatric disorders. Biochim Biophys Acta (2006) 1.12
Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08
Advances in the treatment of depression. NeuroRx (2006) 1.03
Integrated neurobiology of bipolar disorder. Front Psychiatry (2014) 0.93
Rapid antidepressant effects: moving right along. Mol Psychiatry (2013) 0.93
Neuroplasticity in depressed individuals compared with healthy controls. Neuropsychopharmacology (2013) 0.92
Advances in the treatment of anxiety: targeting glutamate. NeuroRx (2006) 0.90
Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat (2010) 0.89
Is bipolar disorder a mitochondrial disease? J Psychiatry Neurosci (2007) 0.88
BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord (2010) 0.88
Chronic lithium chloride administration to rats elevates glucose metabolism in wide areas of brain, while potentiating negative effects on metabolism of dopamine D2-like receptor stimulation. Psychopharmacology (Berl) (2006) 0.83
Finding what you are not looking for: strategies for developing novel treatments in psychiatry. NeuroRx (2006) 0.82
A mitochondrial bioenergetic basis of depression. J Bioenerg Biomembr (2014) 0.81
Neurotransmission and bipolar disorder: a systematic family-based association study. Am J Med Genet B Neuropsychiatr Genet (2008) 0.79
The neurobiological link between OCD and ADHD. Atten Defic Hyperact Disord (2014) 0.79
Repeated administration of imipramine modifies GABAergic transmission in rat frontal cortex. J Neural Transm (Vienna) (2012) 0.79
Basolateral amygdala volume and cell numbers in major depressive disorder: a postmortem stereological study. Brain Struct Funct (2014) 0.78
Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study. Psychopharmacology (Berl) (2008) 0.77
Depressive symptomatology correlates with phantom breast syndrome in mastectomized women. Eur Arch Psychiatry Clin Neurosci (2008) 0.76
Antipsychotic-like effects of a neurotensin receptor type 1 agonist. Behav Brain Res (2016) 0.76
Serotonin versus catecholamine deficiency: behavioral and neural effects of experimental depletion in remitted depression. Transl Psychiatry (2015) 0.76
Atrophy of pyramidal neurons and increased stress-induced glutamate levels in CA3 following chronic suppression of adult neurogenesis. Brain Struct Funct (2013) 0.76
Deficits in cognitive flexibility induced by chronic unpredictable stress are associated with impaired glutamate neurotransmission in the rat medial prefrontal cortex. Neuroscience (2017) 0.76
Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat (2016) 0.75
Increased pregenual anterior cingulate glucose and lactate concentrations in major depressive disorder. Mol Psychiatry (2016) 0.75
Emerging Novel Treatments for Severe Mood Disorders Involving Cellular Plasticity Cascades. Curr Psychos Ther Rep (2006) 0.75
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
Emotion circuits in the brain. Annu Rev Neurosci (2000) 24.39
Epigenetic programming by maternal behavior. Nat Neurosci (2004) 20.92
The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell (2003) 12.50
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A (1996) 11.37
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci (2003) 10.89
5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci (2005) 10.13
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
Neurobiology of depression. Neuron (2002) 8.56
Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry (1999) 7.87
Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med (2000) 7.79
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
Limbic connections of the orbital and medial prefrontal cortex in macaque monkeys. J Comp Neurol (1995) 6.37
Stress and hippocampal plasticity. Annu Rev Neurosci (1999) 6.31
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
Control of synapse number by glia. Science (2001) 5.38
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci (2002) 5.17
Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry (2000) 4.99
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry (1998) 4.83
GLIA: listening and talking to the synapse. Nat Rev Neurosci (2001) 4.67
The yin and yang of neurotrophin action. Nat Rev Neurosci (2005) 4.45
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2003) 4.44
A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry (2005) 4.33
Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A (1998) 4.16
Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry (2000) 4.03
Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 4.00
Neuroimaging studies of mood disorders. Biol Psychiatry (2000) 3.92
Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry (2005) 3.85
A functional anatomical study of unipolar depression. J Neurosci (1992) 3.85
Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry (2004) 3.85
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci (2003) 3.67
Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci (2004) 3.56
Parkinson's disease. Second of two parts. N Engl J Med (1998) 3.46
Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med (1993) 3.45
Dissociable functions in the medial and lateral orbitofrontal cortex: evidence from human neuroimaging studies. Cereb Cortex (2000) 3.44
Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol (2001) 3.40
Subcortical and ventral prefrontal cortical neural responses to facial expressions distinguish patients with bipolar disorder and major depression. Biol Psychiatry (2004) 3.36
Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry (2004) 3.33
Dissociation Of working memory from decision making within the human prefrontal cortex. J Neurosci (1998) 3.28
Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry (2001) 3.18
The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry (2005) 3.16
A differential pattern of neural response toward sad versus happy facial expressions in major depressive disorder. Biol Psychiatry (2005) 3.15
Perseverative interference in monkeys following selective lesions of the inferior prefrontal convexity. Exp Brain Res (1970) 3.03
Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci U S A (2001) 3.01
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry (2001) 2.92
Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci (1999) 2.86
Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry (2001) 2.67
Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry (1989) 2.67
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav (1997) 2.67
Chronic stress alters dendritic morphology in rat medial prefrontal cortex. J Neurobiol (2004) 2.65
Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry (2001) 2.55
Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther (2001) 2.55
Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry (2002) 2.53
Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol (2002) 2.53
Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res (2000) 2.52
Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci (1999) 2.52
Dendritic reorganization in pyramidal neurons in medial prefrontal cortex after chronic corticosterone administration. J Neurobiol (2001) 2.50
Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartic acid receptor activity. Proc Natl Acad Sci U S A (1998) 2.37
Deep brain stimulation for Parkinson's disease. Curr Opin Neurobiol (2003) 2.36
The increasing medical burden in bipolar disorder. JAMA (2005) 2.33
Mitochondrial dysfunction in bipolar disorder. Bipolar Disord (2000) 2.32
Lithium-induced increase in human brain grey matter. Lancet (2000) 2.31
Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry (2004) 2.27
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry (2005) 2.24
Emotional perseveration: an update on prefrontal-amygdala interactions in fear extinction. Learn Mem (2004) 2.23
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem (2004) 2.21
Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry (2000) 2.21
The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry (2003) 2.19
Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. Neuroreport (1996) 2.18
Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry (1998) 2.17
Antidepressant effect on connectivity of the mood-regulating circuit: an FMRI study. Neuropsychopharmacology (2005) 2.16
Regulation of adult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus. J Neurosci (1995) 2.04
Neural plasticity to stress and antidepressant treatment. Biol Psychiatry (1999) 2.03
Bone mineral density in women with depression. N Engl J Med (1996) 2.03
Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry (1987) 1.98
Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ (2005) 1.95
Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry (2005) 1.95
How does deep brain stimulation work? Present understanding and future questions. J Clin Neurophysiol (2004) 1.91
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry (2005) 1.90
Comparative aspects of amygdala connectivity. Ann N Y Acad Sci (2003) 1.90
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci (2000) 1.86
Cell pathology in bipolar disorder. Bipolar Disord (2002) 1.86
Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science (2004) 1.83
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia (1986) 1.82
Mild, short-term stress alters dendritic morphology in rat medial prefrontal cortex. Cereb Cortex (2005) 1.81
Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav (2002) 1.80
Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry (2005) 1.77
Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry (2005) 1.74
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Antidepressants and neuroplasticity. Bipolar Disord (2002) 1.66
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
STEREOTACTIC TRACTOTOMY IN THE SURGICAL TREATMENT OF MENTAL ILLNESS. J Neurol Neurosurg Psychiatry (1965) 1.65
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Neurobiology of emotion perception I: The neural basis of normal emotion perception. Biol Psychiatry (2003) 6.93
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatry (2003) 6.52
Neurocircuitry of mood disorders. Neuropsychopharmacology (2010) 5.57
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
International Society for Bipolar Disorders Task Force on Suicide: meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord (2014) 4.10
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2007) 3.15
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry (2003) 3.00
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Neural circuits underlying the pathophysiology of mood disorders. Trends Cogn Sci (2011) 2.76
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev (2009) 2.44
Choosing the lesser of two evils, the better of two goods: specifying the roles of ventromedial prefrontal cortex and dorsal anterior cingulate in object choice. J Neurosci (2006) 2.40
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry (2002) 2.01
Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. Neuropsychopharmacology (2003) 1.99
5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol (2009) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry (2002) 1.94
Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther (2009) 1.90
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry (2002) 1.86
Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry (2012) 1.85
Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry (2002) 1.84
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril (2007) 1.82
Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry (2004) 1.82
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry (2002) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry. Neuroimage (2005) 1.57
Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry (2012) 1.55
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep (2007) 1.50
The effects of tryptophan depletion on neural responses to emotional words in remitted depression. Biol Psychiatry (2009) 1.50
Self-regulation of amygdala activation using real-time FMRI neurofeedback. PLoS One (2011) 1.50
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology (2008) 1.41
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med (2010) 1.41
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Match between cue and memory valence during autobiographical memory recall in depression. Psychol Rep (2012) 1.40
Molecular effects of lithium. Mol Interv (2004) 1.39
Cerebral blood flow in immediate and sustained anxiety. J Neurosci (2007) 1.38
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38